Comparative Pharmacology
Head-to-head clinical analysis: ACILAC versus ZIBA RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACILAC versus ZIBA RX.
ACILAC vs ZIBA-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme inhibitor; blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
ZIBA-RX is a combination product containing zinc sulfate and bacitracin. Zinc sulfate acts as a topical astringent and antimicrobial agent, while bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier molecule, preventing incorporation of peptidoglycan into the cell wall.
10 mg orally once daily, with or without food.
500 mg orally twice daily for 7-14 days
None Documented
None Documented
Terminal elimination half-life is 2.5-4 hours; prolonged in renal impairment (up to 10-15 hours in severe cases).
Terminal elimination half-life is 12-18 hours (mean 15 hours) in patients with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal (60-70% unchanged), with 15-25% biliary/fecal.
Renal excretion accounts for 60-70% as unchanged drug; biliary/fecal elimination accounts for 25-30% as metabolites; <5% excreted in feces as unchanged drug.
Category C
Category C
Probiotic
Probiotic